Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Accurate MS Information for Your Patients
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy.
Health Care Resource Use and Cost Of Multiple Sclerosis in Slovakia: Results from the National Cross-Sectional Study.
Papers: 10 Oct 2015 - 17 Oct 2015
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Resisting Arrest
Regional Frontal Perfusion Deficits in Relapsing-Remitting Multiple Sclerosis with Cognitive Decline.
Papers: 8 May 2015 - 15 May 2015
Papers: 14 Aug 2015 - 21 Aug 2015
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Histamine and Immune Biomarkers in CNS Disorders.
Papers: 17 Jul 2015 - 24 Jul 2015
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
Papers: 22 Dec 2015 - 29 Dec 2015
European Multiple Sclerosis Platform 2016 Spring Conference
Papers: 11 Sep 2015 - 18 Sep 2015
Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment.
A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.
The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland.
Cross-disease transcriptomics: Unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature.

Pages